Australia Therapeutic Goods Advertising Code: What Taiwan Brands Must Know

The Therapeutic Goods Advertising Code 2021 (the Code) governs all advertising of therapeutic goods in Australia, including medicines, medical devices, biologicals, and complementary health products. The Code was made under Section 42BAA of the Therapeutic Goods Act 1989 and replaced the previous 2018 version with stricter provisions for digital advertising, social media influencer marketing, and online marketplace listings. Every advertisement for a therapeutic good that is directed at consumers (as opposed to healthcare professionals) must comply with the Code, regardless of the medium, platform, or geographic location of the advertiser. This means that Taiwan brands advertising therapeutic products to Australian consumers through websites, Amazon AU product listings, social media accounts, or email marketing are subject to the Code's requirements.

The Code establishes a fundamental distinction between Listed therapeutic goods (lower risk, identified by AUST L numbers) and Registered therapeutic goods (higher risk, identified by AUST R numbers). Advertising for Listed goods, which include most complementary medicines, over-the-counter pain relievers, and low-risk medical devices, must comply with the general advertising provisions but generally does not require pre-approval from the TGA before publication. Advertising for Registered goods, including prescription medicines and higher-risk medical devices, is subject to additional restrictions and may require TGA pre-approval. For Taiwan exporters, most consumer health products entering Australia will fall into the Listed category, but it is essential to confirm your product's classification before preparing any advertising materials.

The Code applies to any communication that promotes the use of a therapeutic good, including product names, descriptions, claims, images, testimonials, endorsements, and any comparison with other products. Notably, the definition of "advertisement" under the Code is extremely broad and includes not only traditional advertising formats but also product labels and packaging when they contain claims beyond what is approved in the product's ARTG entry, social media posts by brand representatives or paid influencers, website content including FAQ pages and blog posts, Amazon AU product listing titles and bullet points, video content on YouTube or TikTok, and email marketing communications. Taiwan brands must review all consumer-facing content through the lens of the Code before publishing.

Key principles of the Code include that advertisements must not be misleading or deceptive, must not create unrealistic expectations of product effectiveness, must include mandatory statements and warnings required by the product's conditions of listing or registration, and must not use scientific or clinical data in a way that misleads consumers about the evidence base for claims. The Code also prohibits certain advertising practices entirely, including using the word "safe" or "completely safe" without qualification, implying that a therapeutic good is guaranteed to work, and creating an impression that a product is necessary for maintaining health when there is no therapeutic need.

Enforcement of the Code is handled by the TGA's Advertising Compliance section, which investigates complaints received through the TGA complaint portal and conducts proactive surveillance of advertising across digital platforms. In 2024-2025, the TGA received 1,847 advertising complaints, conducted 3,200 proactive compliance assessments of online advertisements, and issued 412 formal compliance actions including infringement notices, enforceable undertakings, and court injunctions. The TGA has demonstrated particular focus on imported health products sold through Amazon AU and other online marketplaces, with 28 percent of compliance actions in the last fiscal year targeting products sold primarily or exclusively online.

Permitted advertising claims for Listed therapeutic goods must be consistent with the indications (therapeutic claims) approved in the product's Australian Register of Therapeutic Goods (ARTG) entry. Each Listed medicine has a set of pre-approved low-level indications selected from the TGA's Permitted Indications List, which contains approximately 1,000 standardized claim statements organized by therapeutic area. For example, a vitamin C supplement might have approved indications including "Helps reduce the severity of common cold symptoms," "Supports immune system health," and "Antioxidant that helps reduce free radicals formed in the body." Advertising may use these exact indications or rephrase them in consumer-friendly language, provided the meaning is not altered or expanded.

Prohibited claims include any therapeutic claim that exceeds the product's approved ARTG indications, any reference to serious diseases or conditions listed in Schedule 2 of the Therapeutic Goods Regulations 1990 (including cancer, diabetes, cardiovascular disease, and mental health disorders), and any claim that a therapeutic good can cure, treat, or prevent a serious condition. For example, a turmeric supplement with an approved indication of "Helps relieve symptoms of mild joint inflammation" cannot be advertised as treating arthritis, preventing joint degeneration, or being effective for rheumatoid arthritis. These restrictions apply equally to explicit claims and implied claims made through imagery, formatting, or contextual placement.

The evidence requirements for advertising claims follow a tiered system based on the type of claim being made. Traditional claims for complementary medicines based on traditional use (e.g., "Traditionally used in Traditional Chinese Medicine to support liver health") require evidence of at least 75 years of documented traditional use in a codified traditional medicine system. Assessed Listed medicines with higher-level claims (e.g., specific efficacy claims supported by clinical trials) have undergone TGA scientific assessment and may make stronger advertising claims consistent with the evidence assessed. Taiwan brands must match their advertising claims to the evidence tier under which their product is listed, as making an assessed-level claim for a traditionally-listed product is a Code violation.

Testimonials and endorsements are permitted under the Code with strict conditions. Consumer testimonials must be genuine, verifiable, and representative of typical user experience. They must not claim or imply cure of a disease, must not discourage consumers from seeking professional medical advice, and must include a disclaimer stating that individual results may vary. Healthcare professional endorsements must clearly identify the person's qualifications, must not imply professional recommendation of the product over other treatments, and must not be used in conjunction with claims that exceed the product's approved ARTG indications. Influencer-paid partnerships must be clearly disclosed under both the Code and the Australian Association of National Advertisers (AANA) Code of Ethics, with #ad or #sponsored tags prominently displayed.

The TGA's pre-approval process for restricted representations is required when advertising makes claims about certain conditions or uses specific types of content that go beyond standard low-level indications. Restricted representations include references to conditions listed in Appendix 6 of the Therapeutic Goods Regulations, use of published studies or clinical trial data in consumer advertising, claims of equivalence or superiority to other therapeutic products, and endorsements by healthcare professionals with specific qualifications. Pre-approval applications are submitted through the TGA Business Services portal and cost AUD 670 per advertisement, with processing times of 20 to 30 business days. Products that have undergone TGA assessment (Assessed Listed medicines) have broader pre-approved claim permissions and may not need individual advertisement pre-approval.

The Therapeutic Goods Advertising Code 2021 explicitly addresses digital advertising and social media with provisions that did not exist in earlier versions. Section 11 of the Code requires that digital advertisements for therapeutic goods include all mandatory statements, warnings, and disclaimers in a manner that is clearly visible without requiring the consumer to click, scroll, or take any additional action. For social media posts, this means mandatory warning text cannot be buried in comments or accessible only through "see more" links; it must be visible in the initial post content. For video advertisements, mandatory statements must be displayed on screen for a sufficient duration to be read (minimum 4 seconds) and spoken in voiceover.

Amazon AU product listings for therapeutic goods require particular attention to Code compliance because the listing structure itself constitutes advertising. The product title, bullet points, A+ content, and product description are all considered advertisements under the Code. Taiwan brands listing therapeutic products on Amazon AU must ensure that the product title does not include therapeutic claims that exceed the ARTG-approved indications, bullet points do not use superlative language ("best," "most effective," "guaranteed") or reference serious diseases, A+ content images do not imply therapeutic outcomes not supported by the product's indication set, and the product description includes all mandatory warning statements. Amazon AU has implemented its own therapeutic goods compliance checks in partnership with the TGA, and non-compliant listings may be suppressed without warning.

Social media advertising through platforms such as Instagram, Facebook, TikTok, and YouTube must comply with the Code regardless of whether the content is organic or paid. This applies to the brand's own social media accounts, paid advertisements through platform advertising systems, sponsored posts by influencers or content creators, and user-generated content that the brand shares or reposts. If a brand reposts a customer testimonial that makes non-compliant therapeutic claims, the brand is responsible for the Code violation, not the original poster. Taiwan brands should establish clear social media content guidelines that list approved claim language and prohibited terms, and all social media content should be reviewed against these guidelines before posting.

Google Ads and search engine marketing for therapeutic products in Australia face additional restrictions beyond the Code. Google's healthcare advertising policies for Australia require advertisers to be certified through Google's healthcare advertiser verification program, which involves submitting proof of ARTG listing and business documentation. Bing Ads has similar but less formalized requirements. Paid search advertisements must not use ad copy that implies cure or guaranteed outcomes, must not use countdown timers or urgency language ("limited time," "act now") in conjunction with therapeutic claims, and must link to a landing page that includes all mandatory product information. Cost-per-click for health product keywords in Australia ranges from AUD 0.80 to AUD 3.50, making it a viable but compliance-intensive customer acquisition channel.

For Taiwan brands managing multi-market digital advertising, it is critical to maintain separate advertising content for the Australian market rather than using the same claims approved in other countries. The United States, for example, permits structure/function claims for dietary supplements that would be considered therapeutic claims requiring ARTG listing in Australia. Similarly, claims permitted under Taiwan's own food and supplement advertising regulations may violate the Australian Code. LNH31 Global recommends creating an Australia-specific advertising compliance matrix that maps each product to its ARTG-approved indications and identifies the exact claim language that is permitted for use across all Australian advertising channels.

Penalties for Therapeutic Goods Advertising Code violations are among the most severe in Australia's consumer protection framework. Civil penalty provisions under the Therapeutic Goods Act 1989 impose maximum fines of AUD 1,111,600 per contravention for corporations and AUD 222,320 per contravention for individuals (as indexed for FY 2026). Each individual advertisement constitutes a separate contravention, so a social media campaign with 10 non-compliant posts could theoretically attract penalties exceeding AUD 11 million. Criminal penalties also apply for the most egregious violations, including advertising that endangers public health, with maximum fines of AUD 888,000 for corporations and 5 years imprisonment for individuals.

The TGA employs a graduated enforcement approach, starting with compliance notices that provide 28 days to rectify the violation, followed by infringement notices with fixed penalties of AUD 13,320 per notice for corporations, enforceable undertakings requiring the advertiser to implement specific corrective actions and compliance programs, and court proceedings for repeat offenders or serious violations. The TGA also has the power to publish details of enforcement actions on its website, which serves as both a deterrent and a source of reputational harm for non-compliant companies. In the 2024-2025 fiscal year, the TGA collected AUD 4.2 million in advertising compliance penalties, with imported health products representing approximately 40 percent of the penalty value.

The self-certification process allows advertisers of Listed therapeutic goods to self-assess their advertisements against the Code without submitting them to the TGA for pre-approval. Self-certification requires the advertiser to complete a standardized checklist confirming that the advertisement meets each applicable provision of the Code, maintain records of the self-certification assessment for five years, and be able to produce the self-certification records to the TGA upon request. The self-certification process does not absolve the advertiser of liability for non-compliant advertisements; it simply means that TGA pre-approval is not required. Taiwan brands should treat self-certification as a rigorous internal review process, ideally conducted by a qualified regulatory affairs specialist familiar with Australian therapeutic goods law.

A practical compliance framework for Taiwan brands includes the following elements. First, maintain a current copy of the ARTG entry for each product, including all approved indications and mandatory statements. Second, create an approved claims library that lists the exact claim language permitted for each product, translated into marketing-friendly formats that remain faithful to the approved indications. Third, establish a content review process whereby all advertising content (product listings, social media posts, website copy, packaging text) is reviewed against the approved claims library before publication. Fourth, train all marketing staff, social media managers, and any external agencies on the Code requirements and the approved claims library. Fifth, conduct quarterly advertising audits across all channels to identify and correct any non-compliant content before TGA surveillance detects it.

Taiwan brands that invest in advertising compliance upfront will find that the Australian market rewards transparent, evidence-based health product marketing. Australian consumers are highly educated and skeptical of exaggerated health claims, and brands that communicate honestly about their product benefits build stronger customer loyalty and higher lifetime value. The compliance investment for a typical product line of 5 to 10 SKUs is approximately AUD 10,000 to AUD 25,000 for initial compliance setup (claims library, content audit, staff training) plus AUD 3,000 to AUD 8,000 per year for ongoing monitoring and updates. This is a modest investment relative to the AUD 6.8 billion Australian complementary medicines market.